Telix Cleared to Commence Renal Cancer Imaging Study in Japan
Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in...
Read moreLatest News
Category: Clinical
First Australian Patient Dosed in ZIRCON Phase III Trial
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at...
Read more
Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical...
Read more
Strategy Update – Acceleration of Prostate Cancer Therapy Program
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)...
Read more
Telix Pharmaceuticals & Radboud University Medical Centre Conclude Clinical Collaboration Agreement
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical...
Read more
Telix Pharmaceuticals and Memorial Sloan Kettering Cancer Center Announce Renal Cancer Collaboration
Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center...
Read more
Telix Pharmaceuticals and AMNI Partner for Prostate Cancer Imaging
Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA...
Read more
Telix and University of Melbourne Establish Cancer Translational Research Partnership
Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of...
Read more